Neugut AI, et al. - Given that patients with metastatic colon cancer treated with infusional 5-fluorouracil (5FU)/leucovorin with either oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) had a comparable progression-free survival benefit vs patients who received 5FU/leucovorin alone, researchers studied the patterns and predictors of use for first-line FOLFOX and FOLFIRI in stage IV colon cancer. Using the Surveillance, Epidemiology and End-Results [SEER]-Medicare linked dataset, they identified patients with newly diagnosed stage IV colon cancer between the years 2005-2013 who received either first-line FOLFOX or FOLFIRI. Findings suggested an association of FOLFOX with later year of diagnosis, being female, and living in the southern region of the US. Investigators noted that most SEER-Medicare patients received FOLFOX as a first-line treatment for stage IV colon cancer, but not FOLFIRI. There were several demographic and clinical factors were related to the use of each specific regimen. For both groups, no difference in survival was detected.